EGFR and non-small cell lung carcinoma: Osimertinib is approved by the FDA and Health Canada for the treatment of advanced NSCLC with the T790M mutation that progressed on prior EGFR TKI, and for first-line treatment of EGFR mutation-positive NSCLC (L858R and exon 19 deletions).